Doxy PEP

29 Jan Doxy PEP

The purpose of this study is to understand if taking an antibiotic called doxycycline by mouth as soon as possible after sexual contact without a condom can reduce the risk of sexually transmitted infections (STIs), including gonorrhea, chlamydia and syphilis. The study will also look at the safety of doxycycline PEP and the impact that PEP may have on the bacteria that cause STIs as well as on bacteria that normally live on the body. While doxycycline is approved by the Food and Drug Administration (FDA), taking doxycycline immediately after sexual contact to prevent infection is investigational and is not approved by the FDA for this use. Participants will take part in the study for 1 year.

Participant Eligibility

Inclusion criteria:
-Willing and able to give written informed consent
– Age > 18 years
-Male sex at birth
-Previously HIV-diagnosed OR
HIV-seronegative at the time of last test within the past three months and a current prescription for PrEP (both daily or event-driven PrEP permitted) or plan to start PrEP within 30 days after the enrollment visit
-Condomless anal or oral sexual contact with ≥ 1 male sex-at-birth partners in the past 12months
-Diagnosed with GC, CT or syphilis in the past 12 months.
Note: self report of STI is acceptable if documentation not available. If the participant reports an incident STI in the past year at the same clinic where the participant will be enrolled, this diagnosis should be confirmed by chart review prior to enrollment. If the diagnosis from this clinic cannot be confirmed, the participant should not be enrolled. If the STI was reported

Contact

Rodney Perkins
(206) 265-9153